Climb Bio Inc CLYM · Stock Open Climb Bio Inc in new tab
Analyst price targets
Recent rating changes, newest first
Climb Bio Inc Analysis (CLYM)
Is Climb Bio Inc a good investment? Climb Bio Inc (CLYM) is currently trading at 9.33 USD. Market analysts have a consensus price target of 27.87 USD. This suggests a potential upside from current levels.
Earnings Schedule: Climb Bio Inc is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.00.
Investor FAQ
Does Climb Bio Inc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Climb Bio Inc?
Climb Bio Inc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.82.
Company Profile
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Community Discussion